SELECT Trial: Wegovy Reduces Heart Attacks and Strokes by 20%

The SELECT trial is one of the most significant clinical trials in obesity medicine history. It proved—for the first time—that a weight loss medication can reduce the risk of heart attacks, strokes, and cardiovascular death in people without diabetes.

This trial fundamentally changed how we think about GLP-1 medications: they're not just weight loss drugs. They're cardiovascular drugs.

Why This Trial Matters

Before SELECT, we knew GLP-1 medications reduced cardiovascular events in people with type 2 diabetes. But was this because they improved blood sugar control, or because of something else?

SELECT answered this question by studying people with obesity and heart disease—but without diabetes. The results showed cardiovascular protection occurs independent of any blood sugar effects.

The Trial Design

Who Was Enrolled

Patients had to meet all of these criteria:

• Age ≥45 years
• BMI ≥27 kg/m² (overweight or obese)
• Pre-existing cardiovascular disease (prior heart attack, stroke, or peripheral artery disease)
• No history of diabetes

This was key: by excluding diabetes, the trial could isolate the cardiovascular effects of semaglutide from any blood sugar benefits.

Primary Results

The primary endpoint (MACE) was highly statistically significant (p<0.001). This means the benefit was real and not due to chance.

Benefits Across Subgroups

Remarkably, the cardiovascular benefit was consistent across nearly all subgroups analyzed:

• Men and women—similar benefit
• Different ethnicities—similar benefit
• Different ages—similar benefit
• Different baseline BMI—similar benefit
• Different kidney function—similar benefit

Heart Failure Subgroup

A prespecified analysis examined patients with heart failure at baseline (24% of participants). The results were even more striking:

• Patients with heart failure: 28% reduction in MACE (HR 0.72)
• Patients without heart failure: 16% reduction in MACE (HR 0.84)

Both heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF) showed benefit.

How Does It Work?

Weight loss was significant—participants lost an average of ~10% of body weight. But scientists believe the cardiovascular benefits go beyond weight loss alone:

• Blood pressure reduction—directly reduces cardiovascular strain
• Cholesterol improvements—better lipid profiles
• Reduced inflammation—lower inflammatory markers like CRP
• Improved blood vessel function—direct effects on vascular health
• Beneficial cardiac effects—may protect heart muscle directly

Safety Profile

Side effects were consistent with other semaglutide trials:

• Discontinuation rate: 16.6% semaglutide vs. 8.2% placebo
• Main reason: Gastrointestinal symptoms (nausea, diarrhea)
• No new safety signals emerged in this high-risk population

Interestingly, serious adverse events were actually less common with semaglutide than placebo, likely because the medication was preventing cardiovascular events.

Real-World Confirmation

A 2025 real-world study (SCORE) analyzed over 27,000 patients in US healthcare databases and confirmed SELECT's findings:

• Patients on semaglutide 2.4 mg had lower rates of MACE than matched controls
• Benefits extended to real-world patients outside clinical trial settings
• Results held across different patient subgroups

What This Means for Patients

If you have:

• Previous heart attack, stroke, or peripheral artery disease, AND
• BMI ≥27 (overweight or obese)

...then Wegovy is now FDA-approved not just for weight loss, but specifically to reduce your risk of having another cardiovascular event.

This is a fundamental shift: GLP-1 medications move from "nice to have for weight loss" to "medically indicated to prevent heart attacks and strokes."

Insurance Implications

The FDA approval for cardiovascular risk reduction may help with insurance coverage. Whereas weight loss drugs are often excluded from insurance coverage, medications for cardiovascular disease prevention are more likely to be covered.

However, coverage remains inconsistent and varies significantly by payer.

What SELECT Didn't Answer

• Primary prevention: Would GLP-1s help people with obesity but without existing heart disease?
• Duration: How long should treatment continue for cardiovascular protection?
• Other GLP-1s: Do tirzepatide and other agents provide similar benefits?
• Cost-effectiveness: Is the cardiovascular benefit worth the cost at scale?